Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Huang, Wei Chun ^a,b,c   Ke, Meng Wei ^a   Cheng, Chin Chang ^a,b,c   Chiou, Shih Hwa ^b,d   Wann, Shue Ren ^a   Shu, Chih Wen ^a   Chiou, Kuan Rau ^a,b   Tseng, Ching Jiunn ^a   Pan, Hung Wei ^a   Mar, Guang Yuan ^a   Liu, Chun Peng ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; CONDITIONED MEDIUM; CYTOKINE; INTERLEUKIN DERIVATIVE; MONOCROTALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HUMAN CELL; IL 12ALPHA GENE; IL 12BETA GENE; IL 1BETA GENE; IL 23 GENE; IL 6 GENE; IN VITRO STUDY; INFLAMMATORY CELL; INTERFERON GAMMA GENE; MACROPHAGE; MALE; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CONDITIONED MEDIUM; DISEASE MODEL; GENETICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFLAMMATION; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PULMONARY ARTERY; SECRETION (PROCESS); TRANSPLANTATION;

ADULT; ANIMALS; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKINS; LUNG; MACROPHAGES; MALE; MONOCROTALINE; NF-KAPPA B; PHOSPHORYLATION; PLURIPOTENT STEM CELLS; PULMONARY ARTERY; RATS;

EID: 84959017378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142476     Document Type: Article

References (56)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 (12 Suppl S): 13S-24S. PMID: 15194174
2. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004; 109(2): 159-65. PMID: 14734504
3. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995; 92(18): 8264-8268. PMID: 7667279
4. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest. 2009; 119(7): 2009-2018. doi: 10.1172/JCI33338 PMID: 19487814
5. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012; 302 (4): L363-9. doi: 10.1152/ajplung.00212.2011 PMID: 21964406
6. Ruiter G, de Man FS, Schalij I, Sairras S, Grünberg K, Westerhof N, et al. Reversibility of the monocrotaline pulmonary hypertension rat model. Eur Respir J. 2013; 42(2): 553-6. doi: 10.1183/09031936. 00012313 PMID: 23904554
7. Sahara M, Sata M, Morita T, Nakamura K, Hirata Y, Nagai R, et al. Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation. Circulation. 2007; 115(4): 509-517. PMID: 17242277
8. Montani D, Perros F, Gambaryan N, Girerd B, Dorfmuller P, Price LC, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011; 184(1): 116-23. doi: 10.1164/rccm.201006-0905OC PMID: 21471108
9. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, et al. Inflammation in pulmonary arterial hypertension. Chest. 2012; 141(1): 201-221.
10. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010; 122(9): 920-927. doi: 10.1161/CIRCULATIONAHA.109.933762 PMID: 20713898
11. Martinez FO, Gordon S, Locati M, Mantovani A, et al. Transcriptional profiling of the human monocyteto-macrophage differentiation and polarization: New molecules and patterns of gene expression. J Immunol. 2006; 177(10): 7303-7311. PMID: 17082649
12. Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC, et al. Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-?B. PLoS One. 2012; 7(8): E42507. doi: 10.1371/journal.pone.0042507 PMID: 22880008
13. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003; 73(2): 209-212. PMID: 12554797
14. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidencebased treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl): S78-84. doi: 10.1016/j.jacc.2009.04.017 PMID: 19555861
15. Ho WJ, Lin CP, Wang CL, Hsu LA, Yu KH, Luo SF, et al. Improvement of right ventricular function in pulmonary arterial hypertension with disease-specific therapy-a clinical observational study. Acta Cardiol Sin. 2014; 30: 236-244.
16. Hsu CH, Glassner C, Hsu HH, Maitland MG, et al. Current therapeutics for pulmonary arterial hypertension. Acta Cardiol Sin. 2012; 28: 267-78.
17. Hsu CH, Ho WJ, Huang WC, Chiu YW, Hsu TS, Kuo PH, et al. 2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the management of pulmonary arterial hypertension. Acta Cardiol Sin. 2014; 30: 401-44.
18. Keogh AM, Mayer E, Benza RL, Corris P, Dartevelle PG, Frost AE, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl): S67-77. doi: 10.1016/j.jacc.2009.04.016 PMID: 19555860
19. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ, et al. Rescue of monocrotalineinduced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: Efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005; 96(4): 442-450. PMID: 15692087
20. Ormiston ML, Deng Y, Stewart DJ, Courtman DW, et al. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Am J Respir Cell Mol Biol. 2010; 43(5): 546-54. doi: 10.1165/rcmb.2009-0152OC PMID: 19995942
21. Zhang ZH, Lu Y, Luan Y, Zhao JJ, et al. Effect of bone marrow mesenchymal stem cells on experimental pulmonary arterial hypertension. Exp Ther Med. 2012; 4(5): 839-843. PMID: 23226736
22. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114(6): 763-76. PMID: 14505575
23. Laugwitz KL, Morretti A, Lam J, Gruber P, Chen YH, Woodard S, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005; 433(7026): 647-53. PMID: 15703750
24. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007; 115(7): 896-908. PMID: 17283259
25. Caspi O, Huber I, Kehat I, Habib M, Arbel G, Gepstein A, et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J Am Coll Cardiol. 2007; 50(19): 1884-93. PMID: 17980256
26. Laflamme MA, Zbinden S, Epstein SE, Murry CE, et al. Cell-based therapy for myocardial ischemia and infarction: Pathophysiologic mechanisms. Annu Rev Pathol. 2007; 2: 307-309. PMID: 18039102
27. Van Laake LW, Passier R, Monshouwer-kloots J, Verkleij AJ, Lips DJ, Freund C, et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007; 1(1): 9-24. doi: 10.1016/j.scr.2007.06.001 PMID: 19383383
28. Jodele S, Hirsch R, Laskin B, Davies S, Witte D, Chima R, et al. Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2013; 19(2): 202-7. doi: 10.1016/j.bbmt.2012.08.022 PMID: 22960385
29. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4): 663-676. PMID: 16904174
30. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5): 861-872. PMID: 18035408
31. Gu M, Nguyen PK, Lee AS, Xu D, Hu S, Piews JR, et al. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. Circ Res. 2012; 111(7): 882-93. doi: 10.1161/CIRCRESAHA.112.269001 PMID: 22821929
32. Fang IM, Yang CH, Chiou SH, Yang CM, et al. Induced pluripotent stem cells without c-Myc ameliorate retinal oxidative damage via paracrine effects and reduced oxidative stress in rats. J Ocul Pharmacol Ther. 2014; 30(9): 757-70. doi: 10.1089/jop.2014.0020 PMID: 25121987
33. Liu YY, Li LF, Yang CT, Lu KH, Huang CC, Kao KC, et al. Suppressing NF-?B and NKRF pathways by induced pluripotent stem cell therapy in mice with ventilator-induced lung injury. PLoS One. 2013; 8(6): E66760. PMID: 23840526
34. Yang KY, Shih HC, How CK, Chen CY, Hsu HS, Yang CW, et al. IV delivery of induced pluripotent stem cells attenuates endotoxin-induced acute lung injury in mice. Chest. 2011; 140(5): 1243-53. doi: 10. 1378/chest.11-0539 PMID: 21835903
35. Johnson JL, Jenkins NP, Huang WC, Gregoli KD, Sala-Newby GB, Scholtes PW, et al. Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability. Mediators Inflamm. 2014. doi: 10.1155/2014/276457
36. Reel B, Sala-Newby GB, Huang WC, Newby AC, et al. Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes. Br J Pharmacol. 2011; 163(8): 1679-90. doi: 10.1111/j.1476-5381.2011.01298.x PMID: 21371008
37. Golpon HA, Fadok VA, Taraseviciene-Stewart L, Scerbavicius R, Sauer C, Welte T, et al. Life after corpse engulfment: Phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J. 2004; 18(14): 1716-1718. PMID: 15345697
38. Voelkel NF, Cool C, Taraceviene-Stewart L, Geraci MW, Yeager M, Bull T, et al. Janus face of vascular endothelial growth factor: The obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med. 2002; 30(5 Suppl): S251-S256. PMID: 12004244
39. Voelkel NF, Cool C. Pathology of pulmonary hypertension. Cardiol Clin. 2004; 22(3): 343-351. PMID: 15302355
40. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 2006; 168(2): 659-669. PMID: 16436679
41. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med. 2006; 174(4): 437-445. PMID: 16728715
42. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009; 10: 6. doi: 10.1186/1465-9921-10-6 PMID: 19173740
43. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009; 104(2): 236-244. doi: 10.1161/CIRCRESAHA. 108.182014 PMID: 19074475
44. Dorronsoro A, Ferrin I, Salcedo JM, Jakobsson E, Fernández-Rueda J, Lang V, et al. Human mesenchymal stromal cells modulate T-cell responses through TNF-?-mediated activation of NF-?B. J Neurosci Res. 2013; 91(11): 1440-9. doi: 10.1002/jnr.23267 PMID: 23996632
45. Wang H, Nagai A, Sheikh AM, Liang XY, Yano S, Mitaki S, et al. Human mesenchymal stem cell transplantation changes proinflammatory gene expression through a nuclear factor-?B-dependent pathway in a rat focal cerebral ischemic model. Int Immunopharmacol. 2014; 22(1): 31-40.
46. Ogulur I, Gurhan G, Kombak FE, Filinte D, Barlan I, Akkoc T, et al. Allogeneic pluripotent stem cells suppress airway inflammation in murine model of acute asthma. Int Immunopharmacol. 2014; 22(1): 31-40. doi: 10.1016/j.intimp.2014.06.011 PMID: 24957687
47. Tatarishvili J, Oki K, Monni E, Koch P, Memanishvili T, Buga AM, et al. Human induced pluripotent stem cells improve recovery in stroke-injured aged rats. Restor Neurol Neurosci. 2014; 32(4): 547-58. doi: 10.3233/RNN-140404 PMID: 24916776
48. Morin C, Hiram R, Rousseau E, Blier PU, Fortin S, et al. Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2014; 307(4): H574-86. PMID: 24929859
49. Li L, Wei C, Kim IK, Janssen-Heininger Y, Gupta S, et al. Inhibition of nuclear factor-?B in the lungs prevents monocrotaline-induced pulmonary hypertension in mice. Hypertension. 2014; 63(6): 1260-9. doi: 10.1161/HYPERTENSIONAHA.114.03220 PMID: 24614212
50. Jonigk D, Al-Omari M, Maegel L, Müller M, Izykowski N, Hong J, et al. Anti-inflammatory and immunomodulatory properties of ?1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A. 2013; 110(37): 15007-12. doi: 10.1073/pnas.1309648110 PMID: 23975926
51. Pott GB, Chan ED, Dinarello CA, Shapiro L, et al.Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009; 85(5): 886-95. doi: 10.1189/jlb.0208145 PMID: 19197072
52. Ehlers MR. Immune-modulating effects of alpha-1 antitrypsin. Biol Chem. 2014; 395(10): 1187-1193. doi: 10.1515/hsz-2014-0161 PMID: 24854541
53. Lockett AD, Kimani S, Ddungu G, Wrenger S, Tuder RM, Janciauskiene SM, et al.?1-antitrypsin modulates lung endothelial cell inflammatory responses to TNF-?. Am J Respir Cell Mol Biol. 2013; 49(1): 143-150. doi: 10.1165/rcmb.2012-0515OC PMID: 23526215
54. Wöltje M, Tschöke B, von Bülow V, Westenfeld R, Denecke B, Gräber S, et al. CCAAT enhancer binding protein ? and hepatocyte nuclear factor 3? are necessary and sufficient to mediate dexamethasone-induced up-regulation of alpha2HS-glycoprotein/fetuin-A gene expression. J Mol Endocrinol. 2006; 36(2): 261-77. PMID: 16595698
55. Gangneux C, Daveau M, Hiron M, Derambure C, Papaconstantinou J, Salier JP, et al. The inflammation-induced down-regulation of plasma Fetuin-A (?2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighboring binding sites. Nucleic Acids Res. 2003; 31 (20): 5957-70. PMID: 14530444
56. Ombrellino M, Wang H, Yang H, Zhang M, Visnubhakat J, Frazier A, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock. 2001; 15: 181-185. PMID: 11236900